In May, the Federal Circuit affirmed the PTAB on every issue in
12 (80%) cases on appeal from post-grant proceedings, including in
three precedential opinions: Sanofi-Aventis Deutschland GmbH v.
Mylan Pharmaceuticals Inc. (No. 21-1981), Bot M8 LLC v.
Sony Interactive Entertainment LLC (No. 22-1291), and
Medtronic, Inc. v. Teleflex Innovations S.A.R.L. (Nos.
21-2356, -2358, -2361, -2363, and -2365). The Federal Circuit
issued a mixed outcome in 1 (6.67%) appeal and reversed or vacated
every issue in 2 (13.33%) appeals. No appeals were dismissed, which
may occur, for example, when the Federal Circuit determines that it
does not have jurisdiction over an appeal.

Through May 31, 2023, the Federal Circuit cumulatively decided
1,161 appeals from the PTAB in IPRs, CBMs, and PGRs. While the vast
majority of these appeals came from IPR proceedings, the number of
PGR appeals has slowly increased over time.